000			02087nam a2200265 4500
001			ESSALUD
005			20260902151624.0
007			ta
008			t pe ||||| |||| 00| 0 spa d
040			_aBMG
041			_aeng
100			_aSrivastava, Deepak _eAutor _954430
245			_aRemuscularizing the failing human heart
300			_apáginas: 2055-2058
520			_aHeart failure with reduced ejection fraction remains a progressive and ultimately lethal condition for millions of patients worldwide. Although current therapies prolong survival and reduce symptoms, they do not address the fundamental pathologic substrate: the irreversible loss of cardiomyocytes and their replacement with fibrotic scar. Patients with advanced heart failure — particularly those with ischemic heart failure — may lose as many as a billion cardiomyocytes, and the annual mortality among patients with advanced heart failure is approximately 50%. Among patients with heart failure of any severity, the inability of the heart to regenerate muscle and the physiological stress of a dilated failing heart result in a 5-year mortality of approximately 50%. For decades, the notion of replacing lost cells — of truly remuscularizing the human heart — has been a central aspiration of regenerative medicine. Major approaches currently being advanced for cardiac regeneration (see Key Concepts) include unlocking cell division in resident cardiomyocytes, reprogramming of resident cardiac fibroblasts into induced cardiomyocytes, and transplantation of pluripotent stem-cell–derived cardiomyocytes, each with a goal of creating more contractile units.
650			_aCARDIOLOGÍA GENERAL _953638
650			_aCARDIOMIOPATÍA _937409
650			_aMIOCARDITIS _938353
650			_aPERICARDITIS _939732
650			_aCIRUGÍA CARDIOVASCULAR _953947
650			_aINSUFICIENCIA CARDIACA _911699
650			_aTRASPLANTE _97847
773	0		_022717 _922665 _dMassachusetts NEJM Group _oNEJM013 _tThe New England Journal of Medicine _wESSALUD _x0028-4793
942			_cARTICULOS _e2026-08-28 _zsqb
999			_c22893 _d22893